SWM
LTRN icon

Spire Wealth Management’s Lantern Pharma LTRN Stock Holding History

Spire Wealth Management’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,025
Closed -$12K – 2429
2022
Q2 		$12K Sell
2,025
-2,025
-50% -$12.1K ﹤0.01% 1856
2022
Q1 		$29K Hold
4,050
– – ﹤0.01% 1660
2021
Q4 		$32K Buy
4,050
+3,000
+286% +$27.4K ﹤0.01% 1919
2021
Q3 		$12K Hold
1,050
– – ﹤0.01% 2044
2021
Q2 		$15K Hold
1,050
– – ﹤0.01% 1987
2021
Q1 		$19K Buy
+1,050
New +$18.4K ﹤0.01% 2168

Other funds holding LTRN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
WWM
Wolff Wiese Magana Carslbad, California $217M AUM 47.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Spire Wealth Management's LTRN Position: Q3 2022 in Review

Spire Wealth Management sold out of Lantern Pharma (LTRN) in Q3 2022, closing a stake of 2,025 shares — an estimated $12K sold.

Spire Wealth Management first reported a position in LTRN in Q1 2021 and held it in 6 quarters. The position peaked at $32K in Q4 2021. 26 funds tracked by Wall St. Rank hold LTRN as of Q3 2022.

  • Spire Wealth Management reported no remaining Lantern Pharma position as of Q3 2022 after selling out during the quarter.
  • Spire Wealth Management sold 2,025 Lantern Pharma shares in Q3 2022, an estimated $12K.
  • Spire Wealth Management first reported a position in Lantern Pharma in Q1 2021 and held it in 6 quarters.
  • Spire Wealth Management's Lantern Pharma position peaked at $32K in Q4 2021.
  • 26 funds tracked by Wall St. Rank held Lantern Pharma as of Q3 2022.

Based on Spire Wealth Management's 13F filing for Q3 2022, filed 7 Nov 2022.